A Phase I/IIa Open-label Dose Escalation Study to Assess the Safety, Tolerability and Preliminary Efficacy of AT9283 in Patients with Intermediate or High-Risk Myelofibrosis.
Phase of Trial: Phase I/II
Latest Information Update: 02 Jun 2011
At a glance
- Drugs AT 9283 (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions; Therapeutic Use
- 12 Mar 2011 New trial record